iRhythm Holdings, Inc (IRTC) News & EventsIRTCiRhythm Holdings, Inc

iRhythm Updates on Cybersecurity Incident Notification

"iRhythm provided an update regarding the cybersecurity incident previously disclosed in June, 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals. As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity professionals experienced in handling these types of incidents. After completing the forensic investigation, iRhythm learned certain data it stores was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026. Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth. iRhythm has no evidence that any personal information has been or will be used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information. Out of an abundance of caution, those served by iRhythm are encouraged to take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis. iRhythm has also established a call center to address questions from impacted individuals. Representatives are available from 8:00 a.m. to 8:00 p.m. Eastern time, Monday through Friday, excluding major U.S. holidays, at 1-844-770-7175. As iRhythm previously reported, the company has not identified any impact to our products, our clinical or medical device systems, our connections to customers, our manufacturing and distribution operations, patient safety, or our ability to meet patient needs. In addition, iRhythm does not store or retain individual financial account information or payment card information. The company continues to believe, as previously stated in the Current Report on Form 8-K dated June 15, 2026, that the incident is not reasonably likely to have a material impact on the company's financial condition or results of operations. iRhythm is committed to maintaining the privacy and security of personal information in its possession and has taken precautions to safeguard it. iRhythm regularly evaluates and modifies its practices and internal controls to safeguard the security and privacy of the information it maintains and is taking steps to mitigate the risk to individuals impacted by this incident."

iRhythm Reports Q2 Revenue of $224.17M, Exceeds Expectations

Reports Q2 revenue $224.17M, consensus $219.32M. "Our second quarter results reflect strong execution across the business, with broad-based growth, meaningful margin expansion, and continued progress against our strategic priorities," said Quentin Blackford, President and Chief Executive Officer of iRhythm. "We are driving adoption across an increasingly diverse set of care settings and channels, including primary care, while continuing to invest in the capabilities that we believe will shape the future of healthcare. We are also thrilled to have entered into a definitive agreement to acquire VitalConnect, a transaction we believe will allow us to serve more patients, while also creating long-term value for clinicians and stockholders."

iRhythm Acquires Vital Connect for $287.5 Million

iRhythm Holdings announced that it and its wholly owned subsidiary, iRhythm Technologies, Inc., have entered into a definitive agreement to acquire Vital Connect, Inc., a privately held leader in wearable biosensor technology and ambulatory cardiac monitoring. Upon closing, the transaction is expected to immediately expand iRhythm's addressable market and advance its evolution into a broader cardiac monitoring and intelligence platform. VitalConnect includes an FDA-cleared platform spanning multiple cardiac monitoring modalities and multi-vitals monitoring capabilities designed for hospital and remote care settings. iRhythm intends to acquire VitalConnect for total consideration of approximately $287.5 million. The consideration is expected to consist of approximately $237.5 million in cash and approximately $50 million in iRhythm common stock. The cash portion is expected to be funded from existing cash on iRhythm's balance sheet. "This combination represents a significant next step in iRhythm's evolution from ambulatory cardiac monitoring to a broader cardiac monitoring and intelligence platform," said Quentin Blackford, President and Chief Executive Officer of iRhythm. "VitalConnect adds complementary mobile cardiac telemetry , multi-vitals and hospital monitoring capabilities that complement Zio and meaningfully expand the categories of patients and customers we can serve. By bringing these capabilities onto iRhythm's commercial platform, we believe we can accelerate our growth, deepen customer partnerships and reach more patients across the continuum of care."